Literature DB >> 11416708

Primary aldosteronism: a practical approach to diagnosis and treatment.

R B Thakkar1, S Oparil.   

Abstract

Primary aldosteronism (PA) may account for as many as 10%-14% of hypertension cases. The plasma aldosterone concentration/plasma renin activity ratio is a simple screening test for PA that should be performed in all patients with refractory/severe hypertension, spontaneous or provoked (by diuretics) hypokalemia, or a requirement for excessive potassium supplementation to maintain normokalemia. PA can be confirmed by a fludrocortisone suppression test or 24-hour urine collection for aldosterone. Confirmatory testing should be followed by high-resolution computerized tomography of the adrenal glands to distinguish bilateral hyperplasia or an adenoma. A solitary tumor greater than 1 cm in size in a younger patient is an indication for surgery; all other (nondiagnostic) findings should be followed by bilateral adrenal venous sampling (if available) to identify a unilateral cause of PA. Treatment for a lateralizing positive study is surgical; spironolactone or another mineralocorticoid receptor antagonist is the treatment of choice for a nonlateralizing study. If adrenal venous sampling is not readily available, patients may be successfully treated pharmacologically.

Entities:  

Mesh:

Year:  2001        PMID: 11416708      PMCID: PMC8101802          DOI: 10.1111/j.1524-6175.2001.00496.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  31 in total

1.  Potentially high prevalence of primary aldosteronism in a primary-care population.

Authors:  P O Lim; P Rodgers; K Cardale; A D Watson; T M MacDonald
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

Review 2.  Primary aldosteronism.

Authors:  R D Gordon
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

Review 3.  Primary aldosteronism and its variants.

Authors:  C E Gómez-Sánchez
Journal:  Cardiovasc Res       Date:  1998-01       Impact factor: 10.787

Review 4.  Glucocorticoid-remediable aldosteronism.

Authors:  G H Williams; R G Dluhy
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

Review 5.  Correctable subsets of primary aldosteronism. Primary adrenal hyperplasia and renin responsive adenoma.

Authors:  I Irony; C E Kater; E G Biglieri; C H Shackleton
Journal:  Am J Hypertens       Date:  1990-07       Impact factor: 2.689

Review 6.  Primary aldosteronism: diagnosis and treatment.

Authors:  W F Young; M J Hogan; G G Klee; C S Grant; J A van Heerden
Journal:  Mayo Clin Proc       Date:  1990-01       Impact factor: 7.616

7.  Primary aldosteronism.

Authors:  W R Litchfield; R G Dluhy
Journal:  Endocrinol Metab Clin North Am       Date:  1995-09       Impact factor: 4.741

8.  Medical management of aldosterone-producing adenomas.

Authors:  R P Ghose; P M Hall; E L Bravo
Journal:  Ann Intern Med       Date:  1999-07-20       Impact factor: 25.391

9.  Factors influencing outcome of surgery for primary aldosteronism.

Authors:  O Celen; M J O'Brien; J C Melby; R M Beazley
Journal:  Arch Surg       Date:  1996-06

10.  High incidence of primary aldosteronism in 199 patients referred with hypertension.

Authors:  R D Gordon; M Stowasser; T J Tunny; S A Klemm; J C Rutherford
Journal:  Clin Exp Pharmacol Physiol       Date:  1994-04       Impact factor: 2.557

View more
  4 in total

Review 1.  Adrenocortical hypertension.

Authors:  Angelo Capricchione; Nathaniel Winer; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

2.  Adrenal hyperplasia.

Authors:  J Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 May-Jun       Impact factor: 3.738

3.  Overlapping spironolactone dosing in primary aldosteronism and resistant essential hypertension.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-08-03       Impact factor: 3.738

4.  Adrenocortical hypertension.

Authors:  Angelo Capricchione; Nathaniel Winer; James R Sowers
Journal:  Curr Urol Rep       Date:  2006-01       Impact factor: 2.862

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.